KY Absatou¹, Ouattara A¹, Tondé Issa², Ky AY³, Idogo G¹, Sanou Mahamoudou²* and Sanou I⁴

¹Bogodogo University Teaching Hospital, Burkina Faso
²Charles De Gaulle Pediatric University Teaching Hospital, Burkina Faso
³Word Vision International, Burkina Faso
⁴Tengandogo University Teaching Hospital, Burkina Faso

*Corresponding Author: Sanou Mahamoudou, Charles De Gaulle Pediatric University Teaching Hospital, Burkina Faso.

Received: February 12, 2024; Published: March 03, 2024

Abstract

Background: Cervical cancer represents a major health problem. It is associated with the carriage of some types of high-risk papillomas. In Burkina, data on the prevalence and spectrum of genital papilloma infection in women living with HIV are poorly available.

Objective: To study human oncogenic genital papillomavirus infection in women living with HIV.

Methodology: This was a descriptive and analytical cross-sectional study which took place at CHU B between August 2021-February 2023. It concerned patients living with HIV in whom the search for Human Papillomavirus (HPV) on cervical cells and HIV viral load and CD4 lymphocyte counts were carried out. The Ceiphed GeneXpert® and Cobas® 4800 platforms were used. CD4 quantification was done using the BD FACSCount™ system.

Results: Out of a total of 403 HIV-positive patients, papillomavirus infection was found in 130 (32.3%). Genotypes 16 and 18 represented 33.1% and 15.4%, respectively. Risk factors for HPV infection were a CD4 count < 200 (p = 0.001), between 200 and 500 (p < 0.001) and a vaginal pH ≥ 5 (p < 0.001).

Conclusion: HPV infection is common among HIV (+) women. Several genotypes have been identified. Decreased immunity and increased vaginal pH are factors associated with this infection. Faced with this observation, the prevention of sexually transmitted infections among HIV-positive women appears to be a necessity.

Keywords: Papillomavirus; Precancerous Lesions; Women; HIV; CHU-B

References

1. World Health Organization. Human papillomavirus vaccines: WHO position paper, 2014. Weekly Epidemiology Record 89.43 (2014): 465-491.
2. World Health Organization. Cervical cancer; (2022).
3. Alliance of French-speaking African and Mediterranean Leagues against cancer. Cervical cancer. Cancers in French-speaking Africa. Paris: National League Against Cancer (2017): 46-49.
4. Burkina Faso profile for cervical cancer. World Health Organization - Country profiles for cervical cancer (2021).
5. Bowden SJ., et al. “Human papillomavirus”. Obstetrics, Gynaecology and Reproductive Medicine 4 (2020): 109-118.
6. Chan CK., et al. “Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination - review of current perspectives”. Journal of Oncology (2019): e3257939:11.
7. Bzhalava D., et al. “International standardization and classification of human papillomavirus types”. Virology 476 (2015): 341-314.
8. Ruelle Y and Fiquet L. “HPV detection tests in cervical cancer screening”. Exercise 123 (2016): 24-33.
9. Cissé ML. “Cervical cancer: epidemiology - natural history”. Dakar: Cheikh Anta Diop University (2011).
10. World Health Organization. “Cervical cancer in the WHO African region: current situation and outlook”. Geneva: WHO (2010): 1-6.
11. Berrébi A., et al. “Frequency, persistence and recurrence of HPV lesions of the cervix in HIV-positive patients”. Gynecologie, Obstetrique and Fertilite 5 (2008): 521-524.
12. Sagna T., et al. “Human papillomaviruses prevalence and genital co-infections in HIV-seropositive women in Ouagadougou (Burkina Faso)”. Pakistan Journal of Biological Sciences 19 (2010): 951-955.
13. Djigma FW., et al. “Prevalence and genotype characterization of Human Papillomaviruses among HIV-seropositive in Ouagadougou, Burkina Faso”. Acta Tropica3 (2011): 202-206.
14. Djonouma I. “Human papillomavirus typing in cervical cancer screening in HIV-positive women tives in Bamako, Med Thesis: University of Sciences, Techniques and Technologies of Bamako” (2023).
15. World Health Organization. “HIV management: latest information on treatment monitoring: measurement of viral load and CD4 cell count”. Geneva: WHO (2017): 1-2.
16. Sinayobye J A., et al. “Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda”. Infectious Agents Cancer1 (2014): 40.
17. Menon S., et al. “Epidemiology of HPV genotypes among HIV positive women in Kenya: a systematic review and meta-analysis”. PLoS One10 (2016): e0163965.
18. Cambrea SC., et al. “HPV and HIV coinfection in women from a southeast region of Romania-PICOPIV study”. Medicine6 (2022): 760.
19. Remis RS., et al. “The epidemiology of sexually transmitted co-infections in HIV-positive and HIV-negative African-Caribbean women in Toronto”. BMC Infectious Disease 13 (2013): 550.
20. Monteiro JC., et al. “Prevalence of high risk HPV in HIV-infected women from belém, pará, amazon region of Brazil: a cross-sectional study”. Frontiers in Public Health 9 (2021): 649152.
21. Abel S., et al. “High prevalence of human papillomavirus infection in HIV-infected women living in French Antilles and French Guiana”. PloS One9 (2019): e0221334.
22. Dreyer G. “Clinical implications of the interaction between HPV and HIV infections”. Best Practice and Research Clinical Obstetrics and Gynaecology 47 (2018): 95-106.
23. Akarolo-Anthony SN., et al. “HIV associated high-risk HPV infection among Nigerian women”. BMC Infectious Disease 13 (2013): 521.
24. Ferlay J., et al. “Estimates of worldwide burden of cancer in 2008: Globocan 2008”. International Journal of Cancer 12 (2010): 2893‑2917.
25. Clifford G., et al. “HPV type-distribution in women with and without cervical neoplastic diseases”. Vaccinated3 (2006): 26-34.
26. Rocha-Brischiliari SC., et al. “Risk factors for cervical HPV infection and genotypes distribution in HIV-infected South Brazilian women”. Infectious Agents Cancer1 (2014): 6.
27. Zayats R., et al. “HPV and the Risk of HIV acquisition in women”. Frontiers in Cellular and Infection Microbiology 12 (2022): 1-11.
28. Liu G., et al. “HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis”. AIDS6 (2018): 795-808.
29. Mitra A., et al. “The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?” Microbiome 4 (2016): 58.
30. Clarke MA., et al. “A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection”. BMC Infectious Disease 12 (2012): 33.

Citation

Citation: Sanou Mahamoudou., et al. “Prevalence and Factors Associated with Human Papillomavirus Infection Among Women Living with HIV in Ouagadougou".Acta Scientific Microbiology 7.4 (2024): 03-09.

Copyright

Copyright: © 2024 Sanou Mahamoudou., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.